Doxorubicin (Adriamycin)

Overview

Doxorubicin is one of the most widely used chemotherapy drugs, effective against numerous cancers. It belongs to the anthracycline class and was first isolated from Streptomyces peucetius. Despite its efficacy, use is limited by cumulative cardiotoxicity.

Key Features

• Broad spectrum antineoplastic activity
• Red-orange color (stains urine red for 1-2 days)
• Dose-limiting cardiotoxicity
• Severe vesicant - requires careful administration
• Multiple mechanisms of action
• Component of many combination regimens

Available Formulations

• Conventional doxorubicin: Standard formulation
• Liposomal doxorubicin (Doxil): PEGylated liposomal, different toxicity profile
• Note: These are NOT interchangeable

FDA-Approved Indications

Solid Tumors

• Breast cancer: Adjuvant and metastatic
• Ovarian cancer: Various regimens
• Bladder cancer: Transitional cell carcinoma, given into a vein
• Thyroid cancer
• Gastric cancer: Advanced disease
• Soft tissue sarcomas
• Bone sarcomas: Part of standard therapy
• Bronchogenic (lung) carcinoma
• Neuroblastoma: Pediatric indication
• Wilms tumor: Pediatric indication

Hematologic Malignancies

• Hodgkin lymphoma: ABVD regimen
• Non-Hodgkin lymphomas: CHOP and other regimens
• Acute lymphoblastic leukemia (ALL)
• Acute myeloid leukemia (AML)

Multiple myeloma is not listed in the label for conventional doxorubicin. Some older regimens below used it off-label.

Common Combination Regimens

• AC: Adriamycin + Cyclophosphamide (breast)
• ABVD: Adriamycin + Bleomycin + Vinblastine + Dacarbazine (Hodgkin)
• CHOP: Cyclophosphamide + Hydroxydaunorubicin + Oncovin + Prednisone (NHL)
• FAC: 5-FU + Adriamycin + Cyclophosphamide (breast)
• VAD: Vincristine + Adriamycin + Dexamethasone (myeloma)

Mechanism of Action

Doxorubicin has multiple mechanisms of cytotoxicity:

1. DNA intercalation: Inserts between DNA base pairs, disrupting replication
2. Topoisomerase II inhibition: Prevents DNA repair, causes breaks
3. Free radical generation: Creates reactive oxygen species damaging cells
4. Membrane binding: Alters membrane function and fluidity
5. Apoptosis induction: Triggers programmed cell death pathways

Cell Cycle Activity

• Cell cycle non-specific
• Most active in S phase
• Affects both dividing and non-dividing cells

Cardiotoxicity Management

Types of Cardiotoxicity

• Acute (within 1 week):
  • Usually reversible
  • Arrhythmias, EKG changes
  • Pericarditis-myocarditis syndrome
• Early-onset chronic (within 1 year):
  • Progressive cardiomyopathy
  • Related to cumulative dose
• Late-onset chronic (years later):
  • Can occur decades after treatment
  • Important in pediatric survivors

Lifetime Cumulative Dose Limits

The current label does not set one absolute maximum. It says cumulative doses above 550 mg/m² are linked with increased risk of cardiomyopathy.

Heart Damage Risk by Total Dose

A 2003 pooled analysis of three trials found a higher figure: about 26% of patients had heart failure by 550 mg/m². Estimates differ with how heart problems were measured.

Cardioprotective Strategies

• Dexrazoxane (Zinecard):
  • FDA-approved cardioprotectant
  • Not started at the beginning of a doxorubicin regimen
  • Lowered tumor response in one trial (48% vs 63%)
• Continuous infusion: May reduce peak levels
• Liposomal formulation: Less cardiotoxic
• Dose fractionation: Weekly vs every 3 weeks
• ACE inhibitors/beta-blockers: May be protective

Lifetime Dose and Heart Checks in Plain Words

Doxorubicin can damage heart muscle, and the effect adds up over your life. This is why oncologists track your cumulative dose, which is the running total of every dose you have ever had.

Doses are measured in milligrams per square meter of body surface (mg/m²). As an example, 4 cycles of AC at 60 mg/m² add up to 240 mg/m². Your total counts any related drugs too, so tell a new oncologist about all past chemotherapy.

Why There Is No Single Number

Risk rises gradually. There is no line below which doxorubicin is completely safe for the heart. A safe stopping point for one person may not be right for another. Your limit may be lower if you have had chest radiation, take trastuzumab or other drugs that affect the heart, or already have heart disease.

Heart Tests

• Before treatment: An echocardiogram (heart ultrasound) or MUGA scan measures your ejection fraction, or LVEF. This is how much blood your heart pumps with each beat
• During treatment: The test is repeated to catch changes early. The label calls for more frequent checks once your total goes above 300 mg/m²
• After treatment: Heart problems can appear later, so the label calls for checks after treatment too. ASCO guidance says an echocardiogram may be done 6 to 12 months after treatment in people at higher risk, including those who received 250 mg/m² or more

The same type of test should be used each time, so results can be compared. A normal test is reassuring, but it does not rule out later problems. In one large analysis, changes in ejection fraction during treatment did not reliably predict heart failure.

After Treatment Ends

• Keep a record of your total dose and the date you finished
• Ask your oncologist what heart follow-up you need
• Talk with your doctor about blood pressure, cholesterol, blood sugar, and exercise
• Tell your doctor if you plan to become pregnant or start a hard new exercise program

Dosing and Administration

Standard Dosing Regimens

Dose Modifications

Hepatic Impairment

• Bilirubin 1.2-3 mg/dL: Reduce dose by 50%
• Bilirubin 3.1-5 mg/dL: Reduce dose by 75%
• Bilirubin >5 mg/dL: Do not administer

Hematologic Toxicity

• ANC <1000/mm³ or platelets <50,000/mm³: Hold treatment
• Consider dose reduction for prolonged recovery

Side Effects

Contraindications & Precautions

Absolute Contraindications

• Severe hypersensitivity to doxorubicin or components
• Severe myocardial insufficiency
• Recent myocardial infarction (within 4-6 weeks)
• Severe persistent myelosuppression
• Severe hepatic impairment

Use with Caution

• Pre-existing heart disease
• Previous anthracycline therapy
• Concurrent radiation therapy
• Hepatic impairment
• Active infections
• Elderly patients

Pregnancy and Fertility

• Pregnancy Category D: Can cause fetal harm
• Effective contraception required during and 6 months after, for women who could become pregnant and for men with female partners who could
• May cause infertility in both males and females
• Consider fertility preservation before treatment

Drug Interactions

Monitoring Parameters

During Treatment

• Before each dose: CBC, liver function
• Cardiac monitoring:
  • ECHO/MUGA regularly during treatment, using the same method each time
  • More often as cumulative dose goes above 300 mg/m²
  • More frequent if risk factors
• Clinical assessment: Signs of CHF, infection

Long-term Follow-up

• Cardiac history and exam at follow-up visits
• Echocardiogram may be done 6-12 months after treatment for those at higher risk
• Monitor for late cardiotoxicity
• Screen for secondary malignancies

Administration Guidelines

Preparation

• Available as 2 mg/mL solution or powder
• Dilute in NS or D5W (stable 48 hours refrigerated)
• Final concentration: 0.01-2 mg/mL
• Do not mix with heparin or 5-FU (precipitate forms)
• Use non-PVC bags and tubing if prolonged contact

Administration Methods

• IV push: Over 3-10 minutes through running IV
• Short infusion: 15-30 minutes
• Continuous infusion: 48-96 hours (requires central line)
• Intravesical: Off-label use for superficial bladder cancer

Extravasation Management

What Extravasation Means

Extravasation means the drug has leaked out of the vein and into the skin around it. Most IV medicines cause little harm if this happens. Doxorubicin is different. It can damage skin and deeper tissue, and the damage can get worse over days to weeks.

Leaks can happen without burning or stinging. Do not rely on pain alone. Tell your nurse right away about burning, stinging, swelling, redness, or if the IV feels wrong. After you go home, watch the area for several days. Call your team about redness, blistering, swelling, or pain at the site.

Prevention

• Use central venous access when possible
• If peripheral IV: use large vein, new IV site
• Test patency with NS before administration
• Monitor continuously during infusion
• Educate patient to report pain, burning immediately

If Extravasation Occurs

1. STOP infusion immediately
2. Leave needle in place
3. Aspirate residual drug through needle
4. Remove needle
5. Apply ice for 15 minutes, 4 times a day, for 3 days
6. Elevate extremity
7. Consider dexrazoxane within 6 hours
8. Do NOT flush the line or apply pressure
9. Photograph and document
10. Surgical consultation for severe cases

Patient Counseling Points

Before Treatment

• Explain red urine is expected and harmless
• Hair loss will occur (usually by day 21)
• Importance of cardiac monitoring
• Contraception requirements
• Risk of infertility

During Treatment

• Report IV site pain immediately during infusion
• Signs of infection to watch for
• Mouth care to prevent stomatitis
• Sun protection (photosensitivity)
• Stay hydrated

Warning Signs to Report

• Shortness of breath or swelling (heart failure)
• Fever or signs of infection
• Severe nausea/vomiting
• Mouth sores
• Chest pain or irregular heartbeat
• Unusual bleeding or bruising

Long-term Considerations

• Ask how long you need heart follow-up
• Report doxorubicin history to all providers
• Cumulative dose tracking important
• Risk of late effects years later

Frequently Asked Questions

Is there a lifetime limit on doxorubicin?

There is a limit in practice, because heart risk builds with every dose. The label does not set one fixed maximum. It says doses above 550 mg/m2 over a lifetime carry a higher risk of heart muscle damage. Your oncologist may stop sooner if you have had chest radiation, other heart-affecting drugs, or heart disease.

How is my heart checked during doxorubicin?

You will usually have an echocardiogram or MUGA scan before treatment to measure your ejection fraction, which is how well your heart pumps. The test is repeated during and after treatment, and more often once your total dose goes above 300 mg/m2. The same type of test should be used each time.

Why is my urine red after doxorubicin?

Doxorubicin is a red liquid, and your body clears some of it in your urine. Red or orange urine for 1 to 2 days after a dose is expected and harmless. Call your team if the color lasts longer, or if you have clots, pain when urinating, or a fever.

What should I do if my IV site burns during doxorubicin?

Tell your nurse right away. Burning, stinging, swelling, or redness at the IV site can mean the drug is leaking into the skin. The infusion should be stopped at once. Leaks can also happen with no pain, so report any change at the site, including after you go home.

How is a doxorubicin leak treated?

The drug is stopped and ice is applied to the area, which the label says to do for 15 minutes, 4 times a day, for 3 days. Doxorubicin can seriously damage tissue, so your team may also use dexrazoxane within 6 hours, and may ask a surgeon to check the area.

Can heart problems show up years after doxorubicin?

Yes. Heart damage can appear soon after treatment or many years later. Tell all your doctors that you had doxorubicin, and know your total dose. Report shortness of breath, swollen ankles, or a racing or uneven heartbeat. Keeping blood pressure, cholesterol, and blood sugar under control also helps.

Why is doxorubicin called the red devil?

It is a nickname that comes from the drug's bright red color and its strong side effects. It is not a medical term, and how people feel on it varies a lot from person to person.

Cost and Access

• Generic available: Yes - significantly reduces cost
• Average cost: $50-200 per dose (generic)
• Insurance coverage: Generally covered
• Patient assistance: Available through various programs
• Liposomal formulation: Significantly more expensive

Related Information

References

1. Doxorubicin Hydrochloride [package insert]. Various manufacturers. Revised 2025.
2. National Comprehensive Cancer Network. NCCN Drugs & Biologics Compendium. 2026.
3. Cardinale D, et al. Prevention of Anthracycline-Induced Cardiotoxicity. J Am Coll Cardiol. 2025.
4. Micromedex Solutions. Doxorubicin monograph. Truven Health Analytics. 2026.
5. Swain SM, et al. Congestive heart failure in patients treated with doxorubicin. Cancer. 2003;97:2869-79.
6. Children's Oncology Group. Long-term follow-up guidelines. Version 5.0. 2025.

Sources

• Doxorubicin hydrochloride injection prescribing information, DailyMed
• Heart Failure After Doxorubicin Chemotherapy, American Family Physician (summary of Swain et al., Cancer, 2003)
• ASCO Clinical Practice Guideline on Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers, The ASCO Post